← Leaderboards
Harry Karmouty-Quintana
University Of Texas Hlth Sci Ctr Houston
$5,963,368
Attributed
$5,963,368
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,963,368 · 4
By mechanism
R01$5,807,368 · 3
R03$156,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Shervin Assassi$2,337,912
- Tingting Weng Mills$2,089,049
- Michael R Blackburn$13,626,157
- Angelo Nascimbene$1,822,560
- Martin Lee Blakely$5,204,299
Others in their field
Other Emerging Leaders on “Experimental Models”
- Joel A Lipkin · Four Points Technology, Llc$183,862,844
- Terry Drinkwine · Carahsoft Technology Corporation$93,741,163
- John Hobbs · Suny At Stony Brook$42,194,917
- Christopher Bee · Suny At Stony Brook$41,239,084
- John Damon Chodera · Sloan-Kettering Inst Can Research$18,835,102
- Alan D. Palkowitz · Indiana University Indianapolis$17,630,798
Research focus
Experimental ModelsAffectLungNovel TherapeuticsLung TransplantationPathway InteractionsDepositionIn VivoProteinsCell ProliferationExtracellular MatrixGenesOverexpressionComplexFunctional DisorderPathogenesisMessenger RnaIn VitroPreventHomeoboxInterstitial Lung DiseasesBleomycinDisease ProgressionPulmonary Fibrosis
Grant awards (15)
Ribosome Dysfunction in Lung Fibrosis$722,667
R01 · FY2025 · HL · contact PI
Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis$516,062
R01 · FY2025 · HL · contact PI
Sine Oculis Homeobox Homolog 1 and clusterin in Pulmonary Hypertension associated with Systemic Sclerosis$156,000
R03 · FY2025 · TR · contact PI
Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis$505,741
R01 · FY2024 · HL · contact PI
Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis$88,670
R01 · FY2024 · HL · contact PI
Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis$516,062
R01 · FY2023 · HL · contact PI
Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis$88,670
R01 · FY2023 · HL · contact PI
Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis$520,448
R01 · FY2022 · HL · contact PI
Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis$534,212
R01 · FY2021 · HL · contact PI
3'UTR Shortening in Pulmonary Vascular Disease$388,764
R01 · FY2021 · HL · contact PI
3'UTR Shortening In Pulmonary Vascular Disease$340,796
R01 · FY2021 · HL · contact PI
3'UTR Shortening in Pulmonary Vascular Disease$388,706
R01 · FY2020 · HL · contact PI
3'UTR Shortening in Pulmonary Vascular Disease$388,652
R01 · FY2019 · HL · contact PI
3'UTR Shortening in Pulmonary Vascular Disease$394,151
R01 · FY2018 · HL · contact PI
3'UTR Shortening in Pulmonary Vascular Disease$413,767
R01 · FY2017 · HL · contact PI